GSK reports positive data on daprodustat

Saturday 6 November 2021

United Kingdom

Daprodustat, a candidate drug for the treatment of anaemia due to chronic kidney disease, has generated positive data in five Phase 3 trials – the first oral inhibitor of an enzyme linked to a protein complex to show efficacy without an increased cardiovascular risk. Data from two of the trials were published in The New England Journal of Medicine on 5 November 2021.